Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Sushmita G Shah"'
Autor:
Venugopal Anitha, Radhika Tandon, Sushmita G Shah, Naveen Radhakrishnan, Sankalp Singh, Vanathi Murugesan, Veena Patwardhan, Meenakshi Ravindran
Publikováno v:
Indian Journal of Ophthalmology, Vol 71, Iss 9, Pp 3142-3148 (2023)
Corneal blindness (CB) is one of the leading causes of blindness in India and globally, affecting around 8 million population worldwide. Many of these corneal blind patients may be visually rehabilitated by corneal transplantation (CT). Eye banking p
Externí odkaz:
https://doaj.org/article/9823842d76e84a92911ef05b21d6f66c
Publikováno v:
Indian Journal of Ophthalmology, Vol 71, Iss 10, Pp 3424-3424 (2023)
Background: Although flap-based laser refractive surgeries are being extensively performed worldwide, complications due to the flap may occur years after the procedure leading to severe vision-threatening complications. Purpose: To describe the manag
Externí odkaz:
https://doaj.org/article/1d28815227c54ef38ad5ccba0714af63
Publikováno v:
Indian Journal of Ophthalmology, Vol 68, Iss 11, Pp 2518-2519 (2020)
Externí odkaz:
https://doaj.org/article/01d6b3b32a804d08992b79877e673029
Autor:
Sushmita G Shah, Gaurav Y Shah
Publikováno v:
Indian Journal of Ophthalmology, Vol 68, Iss 7, Pp 1441-1442 (2020)
Externí odkaz:
https://doaj.org/article/a9ed6f00a67a436380643a32aa1e7bfa
Publikováno v:
Indian Journal of Ophthalmology, Vol 67, Iss 8, Pp 1382-1383 (2019)
Externí odkaz:
https://doaj.org/article/0396fa8f69b84f968e87eabd09d4d695
Publikováno v:
European Journal of Ophthalmology. 33:NP23-NP26
Purpose To report a case of corneal scarring following collagen cross linking in a young female. Methods A 24-year-old female presented to us with complaints of decreased vision and a white spot in her left eye following collagen cross linking (CXL)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6445fcd87a355bb2eff633004a23d32
https://doi.org/10.1177/11206721221078152
https://doi.org/10.1177/11206721221078152
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 166:216-226
Delivery of therapeutics to the ocular tissues is challenging due to various anatomical and physiological barriers imposed. Cell penetrating peptides (CPPs) have emerged as potent drug nanocarriers that have been shown to overcome these barriers and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b834a35f486ec9ceeaf9e344c8f8b3
https://doi.org/10.1016/j.ejpb.2021.06.014
https://doi.org/10.1016/j.ejpb.2021.06.014
Publikováno v:
Journal of Interferon & Cytokine Research. 42:137-139
We describe a rare case of a 58-year-old female with ocular surface squamous neoplasia (OSSN) in her left eye. She was treated for 12 months with topical interferon alpha-2b (IFNα-2b) eye drops and OSSN resolved completely. She presented with a whit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9492608e1a68dad6e661bac01c89ecc9
https://doi.org/10.1089/jir.2021.0191
https://doi.org/10.1089/jir.2021.0191
Publikováno v:
Orbit (Amsterdam, Netherlands).
We describe the outcomes of oral mucous membrane grafting as a surgical technique for unilateral lid margin keratinization following radiotherapy. A 47-year- old woman presented with an 8-month history of a white spot in her right eye. She had a hist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::329d0ce30e7774b245b4270d968df490
https://pubmed.ncbi.nlm.nih.gov/34488524
https://pubmed.ncbi.nlm.nih.gov/34488524
Publikováno v:
International journal of pharmaceutics. 600
Natamycin is the only FDA approved drug that is used as a first line of treatment for fungal keratitis caused by filamentous fungi, however natamycin is known for poor corneal penetration. Cell penetrating peptides (CPPs) are emerging nanocarriers fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b823860fffc48ec00d36ca4722f1444
https://pubmed.ncbi.nlm.nih.gov/33737097
https://pubmed.ncbi.nlm.nih.gov/33737097